India’s pharma exports seen soaring to $65 bn by 2030

India’s pharmaceutical exports could double to $65 billion by 2030, driven by a combination of strategies, including a focus on advanced therapeutic areas and complex generics, according to Rubix Data Sciences. From strategic acquisitions by Indian contract development and manufacturing organisations (CDMOs) in the US and Europe to the increasing share of complex generics in their product mix, Indian companies are proactively mitigating external risks. Rubix noted that domestic pharma companies are also entering advanced therapeutic areas, such as oncology, anti-diabetics and the central nervous system, to gain a larger share in key markets. India can potentially secure a position among the top five nations in export value by 2047 by innovating and diversifying its export basket to include speciality generics, biosimilars and innovative products. In FY25, Indian pharma exports reached $30.5 billion, registering a 9.3% jump from the previous year, as per a report.